Research and Markets has announced the addition of the "Bronchitis - Pipeline Review, H2 2016" report to their offering.
Bronchitis pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 4 respectively.
Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked, shortness of breath aggravated by exertion or mild activity, frequent respiratory infections that worsen symptom, wheezing, fatigue, ankle that affects both sides and headaches. Risk factors include smoking, low resistance and gastric reflux.
Bronchitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/pxx72h/bronchitis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005622/en/Business Wire
Last updated on: 28/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.